| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:15110097 | IVTH | 0.00001 - 0.001 M | 0.00001 - 0.001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:17904329 | IVR | 1000 mg/kg/day | 1000 mg/kg/day | Uterotrophic effect | Reproductive endocrine-mediated perturbations |
| PMID:22531466 | IVTH | 0.0000001 - 0.00001 M | 0.0000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:24563381 | IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Increase in cortisol levels | Neurological endocrine-mediated perturbations |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Increased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Increased progestagens levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decreased Dehydroepiandrosterone (DHEA) levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0000000001 - 0.0001 M | 0.0000001 - 0.0000548 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:26186136 | IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| PMID:26751127 | IVTH | 0.00001 - 0.0005 M | 0.00001 - 0.00007 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 - 0.0005 M | 0.00001 - 0.00007 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0005 M | 0.00001 - 0.00007 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0005 M | 0.00001 - 0.00007 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| PMID:28628672 | IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:28735473 | IVTH | 0.00000001 M | 0.00000001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0000001 M | 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00001 M | 0.00001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0000001 M | 0.0000001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| PMID:28808208 | IVTH | 0.0000001 - 0.00001 M | 0.000001 - 0.00001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVTH | 0.0000001 - 0.00001 M | 0.000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:30120946 | IVR | 0.005 mg/L | - | No significant effects observed | - |
| IVR | 0.05 mg/L | 0.05 mg/L | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg/L | 0.025 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects the biochemical composition of testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased weights of epididymis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| PMID:30613871 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects cell metabolism | Metabolic endocrine-mediated perturbations |
| PMID:30823348 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Oxidative stress in liver in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Increased triglycerides level in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects glycogen metabolism in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Increased hepatic glycogen levels in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| PMID:30871434 | IVR | 50 mg/kg/day | 50 mg/kg/day | Induce apoptosis of spermatogenic cells | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | - | No significant effects observed | - | |
| IVR | 25 mg/kg/day | - | No significant effects observed | - | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| PMID:31388671 | IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer |
| IVTH | 0.000001 M | 0.000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| PMID:31424294 | IVR | 5 mg/kg | 5 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.5 - 5 mg/kg | 0.5 - 5 mg/kg | Changes in ovarian morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 - 5 mg/kg | 0.5 - 5 mg/kg | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.05 - 5 mg/kg | 0.05 - 5 mg/kg | Oxidative stress in ovaries | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 - 5 mg/kg | 0.05 - 5 mg/kg | Affects ovarian follicles population | Reproductive endocrine-mediated perturbations | |
| PMID:31514588 | IVR | 0.025 - 0.05 mg/L | 0.025 - 0.05 mg/L | Affects sperm motility | Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/L | 0.05 mg/L | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 - 0.05 mg/L | 0.025 - 0.05 mg/L | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 - 0.05 mg/L | 0.025 - 0.05 mg/L | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Decreased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/L | 0.05 mg/L | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| PMID:31601247 | IVTH | 0.00000001 M | 0.00000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVTH | 0.000001 M | 0.000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:31742322 | IVTH | 0.00000001 - 0.00001 M | 0.00000001 - 0.00001 M | Induce cancer metastasis | Endocrine-mediated cancer |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:31875995 | IVTH | 0.000065 M | 0.000065 M | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations |
| PMID:31995776 | IVTH | 0.000005 - 0.00001 M | 0.000005 - 0.00001 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations |
| PMID:32289607 | IVTH | 0.0000001 - 0.0001 M | 0.0000001 - 0.0001 M | Oxidative stress in granulosa cells | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0001 M | 0.0001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Decreased mitochondrial membrane potential in granulosa cells | Reproductive endocrine-mediated perturbations | |
| PMID:32867778 | IVR | 0.05 mg/kg | 0.05 mg/kg | Decreased body weights | Metabolic endocrine-mediated perturbations |
| PMID:33753083 | IVTH | 0.00000000625 - 0.000000025 M | 0.00000000625 - 0.000000025 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000000025 M | 0.000000025 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000000025 M | 0.000000025 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000000625 - 0.000000025 M | 0.00000000625 - 0.000000025 M | Increase in estradiol/testosterone ratio | Reproductive endocrine-mediated perturbations | |
| PMID:33865937 | IVTH | 0.000001 - 0.000025 M | 0.000001 - 0.000025 M | Altered adipogenesis | Metabolic endocrine-mediated perturbations |
| PMID:33916708 | IVTH | 0.000025 - 0.00005 M | 0.000025 - 0.00005 M | Induce apoptosis of placental cells | Reproductive endocrine-mediated perturbations |
| PMID:34141841 | IVTH | 0.000001 M | 0.00000006 M | Induce apoptosis in adipose tissue | Metabolic endocrine-mediated perturbations |
| PMID:34186270 | IVTH | 0.00000001 - 0.00005 M | 0.00000001 - 0.00005 M | Affects lipid metabolism | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00000001 - 0.000001 M | 0.00000001 - 0.000001 M | Increased leptin levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Decreased adiponectin levels | Metabolic endocrine-mediated perturbations | |
| PMID:34831106 | IVTH | 0.000001 - 0.00001 M | 0.000001 - 0.00001 M | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0001 M | 0.0001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000001 - 0.0001 M | 0.000001 - 0.0001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Affects expression of estrogen receptor-alpha (ER-alpha) | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 - 0.0001 M | 0.000001 - 0.0001 M | Affects expression of estrogen receptor (ER) | Reproductive endocrine-mediated perturbations | |
| PMID:35283775 | IVR | 0.0000002 - 0.00002 mg/day | 0.0000002 - 0.00002 mg/day | Affects fertility | Reproductive endocrine-mediated perturbations |
| PMID:35457000 | IVTH | 0.000000001 M | 0.000000001 M | Elevated insulin levels | Metabolic endocrine-mediated perturbations |
| PMID:35940389 | IVTH | 0.00001 M | 0.00001 M | Induce apoptosis of endometrial cells | Reproductive endocrine-mediated perturbations |
| PMID:36060944 | IVTH | 0.000001 M | 0.000001 M | Affects uterine morphology | Reproductive endocrine-mediated perturbations |
| PMID:36584861 | IVTH | 0.00000001 M | 0.00000001 M | Induce apoptosis of granulosa cells | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000000001 - 0.0000001 M | 0.0000000001 - 0.0000001 M | Induce cancer metastasis | Endocrine-mediated cancer | |
| IVTH | 0.00000001 M | 0.00000001 M | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000000001 - 0.0000001 M | 0.000000001 - 0.0000001 M | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.00000001 M | 0.00000001 M | Affects cell metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:36706583 | IVR | 0.002 - 0.2 mg/kg/day | 0.002 - 0.2 mg/kg/day | Increased adiposity | Metabolic endocrine-mediated perturbations |
| IVR | 0.002 mg/kg/day | 0.002 mg/kg/day | Affects neural development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects neuronal function | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Changes in brain morphology | Neurological endocrine-mediated perturbations | |
| IVR | 0.002 - 0.2 mg/kg/day | 0.002 - 0.2 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| PMID:37164221 | IVR | 1 mg/kg/day | 1 mg/kg/day | Affects penis development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Affects testicular development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:37191987 | IVR | 1.125 mg/L | 1.125 mg/L | Increase in corticosterone levels | Neurological endocrine-mediated perturbations |
| IVR | 1.125 mg/L | 1.125 mg/L | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1.125 mg/L | 1.125 mg/L | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1.125 mg/L | 1.125 mg/L | Increased thymus gland weights | Immunological endocrine-mediated perturbations | |
| IVR | 1.125 mg/L | 1.125 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 1.125 mg/L | 1.125 mg/L | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1.125 mg/L | 1.125 mg/L | Affects developmental process | Developmental endocrine-mediated perturbations | |
| PMID:37298413 | IVTH | 0.000000005 M | 0.000000005 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:37433837 | IVR | 0.0365 - 3.65 mg/kg/day | 0.0365 - 3.65 mg/kg/day | Oxidative stress in liver | Hepatic endocrine-mediated perturbations |
| PMID:37601897 | IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Increased cholesterol levels | Metabolic endocrine-mediated perturbations |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Causes inflammation | Immunological endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Affects expression of estrogen receptor-beta (ER-beta) | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 3 - 5 mg/kg | 3 - 5 mg/kg | Induce testicular damage | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1 - 5 mg/kg | 1 - 5 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 3 - 5 mg/kg | 3 - 5 mg/kg | Alterations in number of leydig cells | Reproductive endocrine-mediated perturbations | |
| IVR | 3 - 5 mg/kg | 3 - 5 mg/kg | Alterations in number of sertoli cells | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased gonadotropin-releasing hormone (GnRH) levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 - 5 mg/kg | 3 - 5 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 - 5 mg/kg | 3 - 5 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 - 5 mg/kg | 3 - 5 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:37800144 | IVR | 3 mg/kg | 3 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 3 mg/kg | 3 mg/kg | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Induce apoptosis in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Causes inflammation | Immunological endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Oxidative stress in testis | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Changes in testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:37816402 | IVTH | 0.0000000001 - 0.00000001 M | 0.0000000001 - 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:37842186 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Affects social behavior | Neurological endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| PMID:38276253 | IVTH | 0.000025 - 0.0001 M | 0.000025 - 0.0001 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000005 - 0.00001 M | 0.0000005 - 0.00001 M | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000025 - 0.0001 M | 0.000025 - 0.0001 M | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000001 - 0.000075 M | 0.0000001 - 0.000075 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.000075 M | 0.00001 - 0.000075 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 - 0.0001 M | 0.000001 - 0.0001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00000005 - 0.0001 M | 0.00000005 - 0.0001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| PMID:38635025 | IVR | 0.04 mg/kg/day | 0.04 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations |
| PMID:38702036 | IVTH | 0.0001 M | 0.0001 M | Induce apoptosis of granulosa cells | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0001 M | 0.0001 M | Oxidative stress in granulosa cells | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Induce mitochondrial dysfunction in granulosa cells | Reproductive endocrine-mediated perturbations | |
| PMID:38808572 | IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Affects intracellular signaling pathway | Metabolic endocrine-mediated perturbations |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Altered lipogenesis | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| PMID:38966215 | IVTH | 0.000025 - 0.0001 M | 0.000025 - 0.0001 M | Increased 17-OH-progesterone to androstenedione ratio | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000005 - 0.0001 M | 0.0000005 - 0.0001 M | Decrease in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.000025 - 0.001 M | 0.000025 - 0.001 M | Increased 17-OH-progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 M | 0.0001 M | Increase in corticosterone levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0001 - 0.00025 M | 0.0001 - 0.00025 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000025 - 0.0001 M | 0.000025 - 0.0001 M | Decrease in testosterone/estradiol ratio | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00005 - 0.00025 M | 0.00005 - 0.00025 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 - 0.001 M | 0.0001 - 0.001 M | Decreased Dihydroxytestosterone (DHT) levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.001 M | 0.00001 - 0.001 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0001 - 0.001 M | 0.0001 - 0.001 M | Decreased androstenedione levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000025 - 0.0001 M | 0.000025 - 0.0001 M | Decreased 21-deoxycortisol level | Neurological endocrine-mediated perturbations | |
| IVTH | 0.0001 - 0.001 M | 0.0001 - 0.001 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.000025 - 0.001 M | 0.000025 - 0.001 M | Decreased 11-deoxycortisol level | Neurological endocrine-mediated perturbations | |
| IVTH | 0.000025 - 0.0001 M | 0.000025 - 0.0001 M | Decreased 17-OH-progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000025 - 0.0001 M | 0.000025 - 0.0001 M | Increased 11-deoxycortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.000001 - 0.00005 M | 0.000001 - 0.00005 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:39002480 | IVR | 0.2 - 1 mg/kg/day | 0.2 - 1 mg/kg/day | Increase in corticosterone levels | Neurological endocrine-mediated perturbations |
| IVR | 0.02 - 1 mg/kg/day | 0.02 - 1 mg/kg/day | Decreased 5-HIAA levels | Neurological endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 - 1 mg/kg/day | 0.02 - 1 mg/kg/day | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| IVR | 0.02 - 1 mg/kg/day | 0.02 - 1 mg/kg/day | Oxidative stress in neurons | Neurological endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.02 - 1 mg/kg/day | 0.02 - 1 mg/kg/day | Causes inflammation | Immunological endocrine-mediated perturbations | |
| IVR | 0.02 - 1 mg/kg/day | 0.02 - 1 mg/kg/day | Decreased serotonin (5-HT) levels | Neurological endocrine-mediated perturbations | |
| IVR | 0.02 - 1 mg/kg/day | 0.02 - 1 mg/kg/day | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| PMID:39520287 | IVTH | 0.000005 - 0.00002 M | 0.000005 - 0.00002 M | Affects steroidogenesis | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000005 - 0.00005 M | 0.000005 - 0.00005 M | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000005 - 0.00005 M | 0.000005 - 0.00005 M | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| PMID:39710178 | IVR | 0.4 - 4 mg/kg | 0.4 - 4 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 0.4 - 4 mg/kg | 0.4 - 4 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 - 4 mg/kg | 0.4 - 4 mg/kg | Alters sperm function | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 - 4 mg/kg | 0.4 - 4 mg/kg | Abnormal sperm morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 - 4 mg/kg | 0.4 - 4 mg/kg | Decreased testosterone levels in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 0.4 - 4 mg/kg | 0.4 - 4 mg/kg | Affects testicular morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 4 mg/kg | 4 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.04 - 4 mg/kg | 0.04 - 4 mg/kg | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 0.4 - 4 mg/kg | 0.4 - 4 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| PMID:39736419 | IVTH | 5 - 125 mg/L | 5 - 125 mg/L | Cancer phenotype | Endocrine-mediated cancer |
| PMID:9449681 | IVTH | 0.0000000001 - 0.00000001 M | 0.0000000001 - 0.00000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000000001 - 0.00000001 M | 0.0000000001 - 0.00000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.